FY2024 Earnings Forecast for CRDL Issued By HC Wainwright

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Equities research analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Cardiol Therapeutics in a research note issued to investors on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now anticipates that the company will earn ($0.38) per share for the year, up from their prior forecast of ($0.44). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q4 2024 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

Cardiol Therapeutics Trading Up 2.5 %

Cardiol Therapeutics stock opened at $1.62 on Friday. Cardiol Therapeutics has a one year low of $0.79 and a one year high of $3.12. The company’s fifty day moving average price is $1.94 and its two-hundred day moving average price is $2.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.49 and a quick ratio of 2.49. The company has a market capitalization of $132.19 million, a price-to-earnings ratio of -4.15 and a beta of 0.91.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC acquired a new stake in Cardiol Therapeutics in the 3rd quarter valued at $27,000. Townsquare Capital LLC acquired a new position in shares of Cardiol Therapeutics during the 3rd quarter worth about $27,000. Jane Street Group LLC bought a new position in shares of Cardiol Therapeutics during the third quarter worth $29,000. Lion Street Advisors LLC raised its stake in Cardiol Therapeutics by 7.9% during the 3rd quarter. Lion Street Advisors LLC now owns 273,281 shares of the company’s stock worth $544,000 after buying an additional 20,000 shares during the period. Finally, Baader Bank Aktiengesellschaft bought a new position in shares of Cardiol Therapeutics during the 2nd quarter valued at about $59,000. 12.49% of the stock is owned by institutional investors.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.